Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11656536 | 0.87 | — | — | |
| SCHEMBL11655209 | 0.83 | ALDH1A1 (0.35) | L3MBTL1 | |
| SCHEMBL3889040 | 0.78 | — | — | |
| SCHEMBL31485041 | 0.77 | — | — | |
| SCHEMBL7493141 | 0.71 | MEN1 (0.45) | L3MBTL1 | |
| SCHEMBL28349871 | 0.70 | — | — | |
| SCHEMBL13057253 | 0.69 | — | — | |
| SCHEMBL30602696 | 0.69 | L3MBTL1 (0.38) | L3MBTL1 | |
| SCHEMBL1573519 | 0.69 | — | — | |
| SCHEMBL237154 | 0.69 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 370 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260137794-A1 | LIGAND-DRUG CONJUGATE AND USE THEREOF | SYSTIMMUNE INC (US) | 2026-05-21 | — | — | US | claimed |
| EP-4527416-A1 | LIGAND-DRUG CONJUGATE AND USE THEREOF | SystImmune, Inc. (US) | 2025-03-26 | — | — | EP | claimed |
| WO-2023222019-A9 | LIGAND-DRUG CONJUGATE AND USE THEREOF | 成都百利多特生物药业有限责任公司 | 2024-11-14 | — | — | WO | claimed |
| CN-118434765-A | BCMA monoclonal antibodies and antibody-drug conjugates | 杭州多禧生物科技有限公司 | 2024-08-02 | — | — | CN | claimed |
| CN-118215676-A | Specific conjugation of antibody drug conjugates | 杭州多禧生物科技有限公司 | 2024-06-18 | — | — | CN | claimed |
| CN-117980327-A | Specific coupling of antibodies | 杭州多禧生物科技有限公司 | 2024-05-03 | — | — | CN | claimed |
| WO-2023222019-A1 | LIGAND-DRUG CONJUGATE AND USE THEREOF | 成都百利多特生物药业有限责任公司 | 2023-11-23 | — | — | WO | claimed |
| CN-117085144-A | Ligand drug conjugate and application thereof | 成都百利多特生物药业有限责任公司 | 2023-11-21 | — | — | CN | claimed |
| CN-116143678-A | Conjugate linker, cell-binding molecule-drug conjugate containing the same, and preparation and application thereof | 杭州多禧生物科技有限公司 | 2023-05-23 | — | — | CN | claimed |
| CN-115443134-A | Conjugates of cell binding molecules and camptothecin analogs | 杭州多禧生物科技有限公司 | 2022-12-06 | — | — | CN | claimed |
| CN-115300640-A | Novel linkers and their use for specific coupling of drugs and biomolecules | 杭州多禧生物科技有限公司 | 2022-11-08 | — | — | CN | claimed |
| CN-108289964-B | Novel linkers and their use for specific coupling of drugs and biomolecules | 杭州多禧生物科技有限公司 | 2022-08-12 | — | — | CN | claimed |
| CN-114040781-A | Formulation of conjugate of TUBULYSIN derivative and cell binding molecule | 杭州多禧生物科技有限公司 | 2022-02-11 | — | — | CN | claimed |
| CN-114040779-A | Conjugates of cell binding molecules containing branched linkers and cytotoxic agents | 杭州多禧生物科技有限公司 | 2022-02-11 | — | — | CN | claimed |
| CN-113698335-A | Specific conjugation of cell binding molecules | 杭州多禧生物科技有限公司 | 2021-11-26 | — | — | CN | claimed |
| CN-113423430-A | Amanitoxin conjugates containing branched linkers | 杭州多禧生物科技有限公司 | 2021-09-21 | — | — | CN | claimed |
| CN-113195487-A | 2, 3-diaminosuccinyl conjugate linkers | 杭州多禧生物科技有限公司 | 2021-07-30 | — | — | CN | claimed |
| CN-112125929-A | Hydrophilic linkers for coupling | 杭州多禧生物科技有限公司 | 2020-12-25 | — | — | CN | claimed |
| CN-111093707-A | Tubulysin homolog conjugates containing branched linkers | 杭州多禧生物科技有限公司 | 2020-05-01 | — | — | CN | claimed |
| CN-110621673-A | Double-stranded linked cytotoxic drug conjugates | 杭州多禧生物科技有限公司 | 2019-12-27 | — | — | CN | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260137794-A1 | LIGAND-DRUG CONJUGATE AND USE THEREOF | CHEK1, ATR, MRE11 | L3MBTL1 282/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.